Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

NuCana

Request full access

Oncology ProTide chemistry transforming chemotherapy agents

Edinburgh, United KingdomFounded 2008Biotech & Life Sciences

About NuCana

NuCana is a clinical-stage biopharmaceutical company, established in 1997 as Prolifix and headquartered in Edinburgh, UK. The company was founded by Hugh Stephen Griffith and Christopher Barry Wood. Hugh Griffith has served as CEO since 2008 and has over 30 years of experience in the biopharmaceutical industry, previously holding positions at Bioenvision, Abbott Laboratories, and Warner-Lambert. In September 2017, NuCana held its Initial Public Offering (IPO) on the Nasdaq, raising approximately $100 million.

The company's business model is centered on its proprietary ProTide technology, a phosphoramidate chemistry platform designed to transform widely used chemotherapy agents, known as nucleoside analogs, into safer and more effective medicines. The technology, developed by the company's late Chief Scientific Officer Professor Christopher McGuigan, aims to overcome cancer cell resistance mechanisms and generate higher concentrations of anti-cancer metabolites within the cancer cells. The ProTide approach involves attaching a protective phosphoramidate cap to a pre-activated nucleoside analog, which facilitates its entry into cancer cells and protects it from breakdown. As a clinical-stage company without product sales, NuCana's operations are funded through equity financing and grants.

NuCana's pipeline focuses on developing ProTide candidates. Its two lead product candidates are NUC-7738 and NUC-3373. NUC-7738, a transformation of 3'-deoxyadenosine, is being evaluated in clinical studies for advanced solid tumors and melanoma. NUC-3373 is a ProTide version of the widely used chemotherapy agent 5-fluorouracil (5-FU) and has been studied in patients with advanced solid tumors, colorectal cancer, and lung cancer. An earlier candidate, Acelarin, a ProTide of gemcitabine, was discontinued after Phase 3 trials in pancreatic and biliary tract cancers were unlikely to meet their primary endpoints. The company collaborates with academic medical centers for its clinical trials and seeks strategic partnerships with other pharmaceutical companies for co-development and commercialization.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2008
Headquarters
Edinburgh, United Kingdom
Listing
IPO 2017
Sector
Biotech & Life Sciences

NuCana in the Edinburgh ecosystem

Live from Dealroom

The NuCana office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇬🇧 United Kingdom87.5%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about NuCana on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See NuCana on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.